Amorphous entecavir p-toluenesulfonate salt and preparation method and medicament application thereof

A technology of p-toluenesulfonate and entecavir, applied in the field of medicine, can solve problems such as differences in bioavailability, and achieve the effects of good stability, improved production quality and high purity

Inactive Publication Date: 2010-07-28
FUJIAN COSUNTER PHARMA
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Different crystalline forms of the same drug may have significantly different bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amorphous entecavir p-toluenesulfonate salt and preparation method and medicament application thereof
  • Amorphous entecavir p-toluenesulfonate salt and preparation method and medicament application thereof
  • Amorphous entecavir p-toluenesulfonate salt and preparation method and medicament application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Put 2.95g of entecavir monohydrate in a reaction flask, add 30.0ml of methanol, stir, heat the reaction solution to 40°C, add a solution made of 2.0g of p-toluenesulfonic acid and 5.0ml of methanol in batches, after the addition, 65 React at ℃ for 3 hours, concentrate under reduced pressure to 12.5ml, cool to 0℃, add 130.0ml ethyl acetate, a viscous solid precipitates, pour off the solvent, wash with 4.0ml ethyl acetate, and dry the residue in vacuum to obtain a white foam Solid para-amorphous entecavir p-toluenesulfonate 4.45g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides amorphous entecavir p-toluenesulfonate salt with high bioavailability, high stability, high yield and high purity. The amorphous entecavir p-toluenesulfonate salt is determined as an amorphous state of entecavir p-toluenesulfonate salt through detections such as X-ray diffraction, infrared absorption spectrum determined by a KBr tablet method, differential scanning calorimetry (DSC) and the like. The invention also relates to a preparation method and medicament application of the amorphous salt.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an antiviral drug entecavir tosylate, an amorphous crystal, a preparation method and a drug application thereof. technical background [0002] Entecavir (Entecavir) is a 2,-pentanecyclodeoxyguanosine analogue, the chemical name is [1S-(1α,3α,4β)]-2-amino-1,9-dihydro-9-[4 -Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, usually monohydrate, the molecular structure is as follows: [0003] Molecular formula C 12 h 15 N 5 o 3 . [0004] Entecavir is a chiral compound, [1S-(1α, 3α, 4β)] optical isomer has a strong anti-hepatitis B (HBV) toxicity. [0005] Entecavir is a highly effective antiviral agent. Clinical studies have shown a good inhibitory effect on hepatitis B virus. Because entecavir has a very high anti-hepatitis B virus activity, a very low dose is sufficient to achieve the desired curative effect. Generally, adults daily Oral administration ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D473/18A61K31/522A61P31/20
Inventor 康惠燕陈国华
Owner FUJIAN COSUNTER PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap